托法替尼治疗难治性硬化症：一个病例系列。

Q4 Medicine

Mediterranean Journal of Rheumatology Pub Date : 2023-08-28 eCollection Date: 2023-09-01 DOI:10.31138/mjr.20230828.ti

Suvankar Dey, Rajdeep Sarkar, Amrita Pradhan, Prasanta Padhan, Debashis Maikap

{"title":"托法替尼治疗难治性硬化症：一个病例系列。","authors":"Suvankar Dey, Rajdeep Sarkar, Amrita Pradhan, Prasanta Padhan, Debashis Maikap","doi":"10.31138/mjr.20230828.ti","DOIUrl":null,"url":null,"abstract":"Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitinib as a steroid-sparing immunomodulatory agent in three patients with refractory scleritis who were either recalcitrant or intolerant to conventional therapy.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"34 3","pages":"367-371"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628867/pdf/","citationCount":"0","resultStr":"{\"title\":\"Tofacitinib in Refractory Scleritis: A Case Series.\",\"authors\":\"Suvankar Dey, Rajdeep Sarkar, Amrita Pradhan, Prasanta Padhan, Debashis Maikap\",\"doi\":\"10.31138/mjr.20230828.ti\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitinib as a steroid-sparing immunomodulatory agent in three patients with refractory scleritis who were either recalcitrant or intolerant to conventional therapy.\",\"PeriodicalId\":32816,\"journal\":{\"name\":\"Mediterranean Journal of Rheumatology\",\"volume\":\"34 3\",\"pages\":\"367-371\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628867/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mediterranean Journal of Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31138/mjr.20230828.ti\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mediterranean Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31138/mjr.20230828.ti","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

托法替尼是一种Janus激酶抑制剂，最近被研究为治疗难治性巩膜炎的潜在药物。尽管使用了系统性免疫抑制剂治疗，但在相当多的患者中，巩膜炎对传统治疗是难治的。在此，我们报道了托法替尼作为一种保留类固醇的免疫调节剂在三名顽固性巩膜炎患者中的应用，这些患者要么对传统治疗不耐受，要么对传统疗法不耐受。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

$Tofacitinib in Refractory Scleritis: A Case Series.$

查看原文本刊更多论文

Tofacitinib in Refractory Scleritis: A Case Series.

Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitinib as a steroid-sparing immunomodulatory agent in three patients with refractory scleritis who were either recalcitrant or intolerant to conventional therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Mediterranean Journal of Rheumatology Medicine-Rheumatology

CiteScore

2.00

自引率

0.00%

发文量

审稿时长

8 weeks